The company completed paracetamol capacity expansion by 1,800 MTPA and the company is now focusing on frugal manufacturing practices to reduce raw material cost and expand margins
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
The company is one of the most profitable companies manufacturing speciality chemicals in India
The pharma laboratory is fully equipped with all the machinery needed to support formulation development, resolve technical challenges, and provide customer demonstrations
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion
Subscribe To Our Newsletter & Stay Updated
